Filing Flows › Axsome Therapeutics (AXSM) › Q3 2026 › vs Q2 2026
Axsome Therapeutics (AXSM) Q3 2026 vs Q2 2026 (quarter over quarter)
Axsome Therapeutics's revenue rose $41.3M (+19%) from $218M in Q2 2026 to $260M in Q3 2026. The biggest changes: Product +$33.6M (+16%); Royalty and Milestone Revenue +$7.7M (+382%).
Axsome Therapeutics, Q3 2026: revenue $260M (+52% year over year), operating margin -4.3%, net loss $12.9M, operating cash flow −$9.5M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product | $250M | $216M | $33.6M | +16% |
| Royalty and Milestone Revenue | $9.7M | $2.0M | $7.7M | +382% |
| Revenue | $260M | $218M | $41.3M | +19% |
| Net loss | $12.9M | $51.3M | −$38.4M | -75% |
| Costs & expenses | $273M | $270M | $2.9M | +1% |
| Operating costs | $271M | $268M | $2.7M | +1% |
| Interest & other, net | $1.7M | $1.5M | $181K | +12% |
| Income tax | $88K | $128K | −$40K | -31% |
| Cost of revenue | $17.8M | $13.6M | $4.2M | +31% |
| Research & development | $50.6M | $46.2M | $4.4M | +9% |
| SG&A | $203M | $208M | −$5.0M | -2% |
| Operating cash sources | $37.6M | $61.8M | −$24.3M | -39% |
| Depreciation & amortization | $1.7M | $1.7M | $3K | +0.2% |
| Share-based compensation | $26.4M | $27.1M | −$792K | -3% |
| Cash used in operations | $9.5M | $33.0M | −$23.5M | -71% |
| Net loss absorbed | $12.9M | $51.3M | −$38.4M | -75% |
| Working capital & other | $24.7M | $10.5M | $14.2M | +135% |
Questions
How much did Axsome Therapeutics's revenue grow quarter over quarter in Q3 2026?
Axsome Therapeutics's revenue rose $41.3M (+19%) from $218M in Q2 2026 to $260M in Q3 2026.
What drove Axsome Therapeutics's revenue change in Q3 2026?
Product +$33.6M (+16%); Royalty and Milestone Revenue +$7.7M (+382%).